Abdullah Alkanan, BDS, MSD/Henry Greenwell, DMD, MSD/Abhishek Patel, BDS, MSD/Margaret Hill, DMD/Brian Shumway, DMD, MS/Jeremy Lowy, DMD, MSD: Twenty-four patients completed this randomized, controlled, blinded clinical trial comparing ridge preservation with a membrane (acellular dermal matrix graft [ADMG]) vs no membrane on buccal overlay graft technique. An intrasocket corticocancellous allograft with a facial overlay xenograft was used for both groups, and an ADMG was used as a membrane with guided bone regeneration in the ADMG group (control group). In the No Membrane group (test group), ADMG was used to cover only the occlusal surface for graft containment, with no membrane on the buccal overlay graft. Final crestal ridge width and vertical ridge height had no significant difference between groups (P > .05). Facial contour was preserved for the ADMG group compared to No Membrane group. Histologic examination showed a high percentage of vital bone for both groups with no significant difference between groups.
Cholangiocarcinoma (CCA) is a deadly and heterogeneous type of cancer characterized by a spectrum of epidemiologic associations as well as genetic and epigenetic alterations. We seek to understand how these features inter-relate in the earliest phase of cancer development and through the course of disease progression. For this, we studied murine models of liver injury integrating the most commonly occurring gene mutations of CCA – including Kras, Tp53, Arid1a and Smad4 – as well as murine hepatobiliary cancer models and derived primary cell lines based on these mutations. Among commonly mutated genes in CCA, we found that Smad4 functions uniquely to restrict reactive cholangiocyte expansion to liver injury through restraint of the proliferative response. Inactivation of Smad4 accelerates carcinogenesis, provoking pre-neoplastic biliary lesions and CCA development in an injury setting. Expression analyses of Smad4-perturbed reactive cholangiocytes and CCA lines demonstrated shared enriched pathways, including cell-cycle regulation, MYC signaling and oxidative phosphorylation, suggesting that Smad4 may act via these mechanisms to regulate cholangiocyte proliferation and progression to CCA. Overall, we showed that TGFβ/SMAD4 signaling serves as a critical barrier restraining cholangiocyte expansion and malignant transformation in states of biliary injury.
30 October 2025 in Journal of Pain and Symptom Management
PURPOSE: Precision therapies have improved outcomes in pancreatic ductal adenocarcinoma (PDAC) and highlight the utility of germline genetic testing (GGT) in clinical decision making. Here, we investigate the association of GGT of individuals diagnosed with PDAC over time to identify changes in testing patterns and the relationship of testing with clinicopathologic parameters and overall survival (OS). METHODS: The frequency of GGT of 979 patients with PDAC treated at the Roswell Park Comprehensive Cancer Center (RPCCC) between 2017 and 2024 was determined. Factors associated with performing testing and having a germline pathogenic variant (GPV) were assessed. OS and the impact of precision treatment were evaluated. RESULTS: Patients with PDAC being treated at RPCCC that had GGT increased from 16.5% in 2017 to 57.6% in 2024. Patients with testing had improved OS compared with patients who did not (HR, 0.46). Individuals of older age, without a personal history of other cancers, without a family history of pancreatic cancer, with advanced disease, and with poorly differentiated tumors were less likely to have testing performed. Individuals with a personal history of other cancers were more likely to have a GPV. Of the 425 patients diagnosed with PDAC that had testing, 58 (13.6%) had a GPV detected. Of patients with testing, 12 had actionable mutations in BRCA1/2 , seven of whom were subsequently treated with olaparib. Three patients harbored actionable mutations in MSH6 , with one patient subsequently treated with pembrolizumab. Patients who received therapy informed by testing results had improved OS (HR, 0.09). CONCLUSION: GGT prevalence has increased at RPCCC and informed treatment decisions. Universal point-of-care testing is being implemented with the goal of completing testing for all patients with PDAC seen at RPCCC.